Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Total Liabilities
Everything the company owes to creditors and other parties.
Annovis Bio, Inc.NYSE: ANVS
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 388.9% from a year ago
Total liabilities stood at $13.12M at the end of Q1 FY2026, up 388.9% from a year earlier and up 210.1% from the prior quarter. Over 3 fiscal years it compounded at -18.1% a year.
Context
- Total liabilities amounted to 80.8% of total assets at the end of Q1 FY2026, up 70.7 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +388.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 4.23M USD
- Year-over-year change
- -8.4%
- 4-year CAGR
- +29.4%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.23M | -8.4% |
| FY2024 | 2024-12-31 | 4.62M | -74.3% |
| FY2023 | 2023-12-31 | 17.96M | +133.3% |
| FY2022 | 2022-12-31 | 7.7M | +411.0% |
| FY2021 | 2021-12-31 | 1.51M | — |
Total Liabilities vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's Mar 2026 total liabilities of $13.12M is the 3rd highest of the 6 companies compared; the peer median is $10.38M.
- Its year-over-year change of +388.9% is the highest of 6, against a peer median of -15.8%.
- Total liabilities amounts to 80.8% of total assets for ANVS, versus a peer median of 54.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $145.39M | +17.4% | -10.4% | 135.5% | |
| Mar 2026 | $20.77M | -15.8% | -13.7% | 84.2% | |
| Mar 2026 | $13.12M | +388.9% | -18.1% | 80.8% | |
| Mar 2026 | $10.38M | -38.1% | -17.4% | 54.2% | |
| Jun 2026 | $9.86M | -77.6% | -2.7% | 24.5% | |
| Mar 2026 | $7.56M | +9.2% | +27.8% | 21.4% | |
| Peer median (excluding ANVS) | $10.38M | -15.8% | -10.4% | 54.2% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.